• EGTA Applications: Modulating Calcium Signaling in Cell Mode

  2026-05-18

  EGTA (egtaizic acid) stands out as a selective calcium chelator, enabling precise control over calcium-dependent processes in neuroprotection and endothelial inflammation models. This article translates leading-edge research into actionable protocols, troubleshooting guidance, and workflow optimizations for advanced cellular assays.

• Pharmacokinetics of CSBTA in MASH: Systemic and Hepatic Insi

  2026-05-17

  This study investigates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. The findings highlight the impact of pathological state and transporter/enzyme modulation on systemic and hepatic exposure, informing more precise dosing strategies in MASLD/MASH research.

• Troglitazone: PPARγ Agonist Workflows in Metabolism & Tumor

  2026-05-16

  Troglitazone is a benchmark PPARγ agonist uniquely suited for dissecting lipid and glucose metabolism as well as tumor microenvironment modulation. This article translates recent high-impact findings and product-specific guidance into actionable protocols, with a focus on advanced oncology use-cases and troubleshooting strategies.

• Nystatin (Fungicidin): Advancing Antifungal Assays with Mech

  2026-05-15

  Explore the advanced roles of Nystatin (Fungicidin) in antifungal research, with a focus on mechanistic depth, resistance challenges, and assay optimization. This article uniquely dissects practical assay decisions and experimental pitfalls, providing insights not covered in standard summaries.

• Ibuprofen as an Anti-Proliferative Agent: Protocols & Optimi

  2026-05-15

  Ibuprofen, or 2-[4-(2-methylpropyl)phenyl]propanoic acid, serves as a robust dual COX inhibitor for cancer and cardiovascular research workflows. This article delivers actionable, evidence-backed guidance for apoptosis induction, cell cycle arrest assays, and troubleshooting, leveraging APExBIO’s high-purity reagent for reproducible, translational results.

• GI 254023X: Precision ADAM10 Inhibition for Endothelial Defe

  2026-05-14

  Explore the advanced role of GI 254023X as a selective ADAM10 inhibitor in safeguarding vascular integrity and dissecting cellular signaling. This in-depth analysis highlights mechanistic nuances and practical assay insights not covered in prior content.

• Novel 14-3-3 Interactors ATG9A and PTOV1 in Cancer Regulatio

  2026-05-14

  This study identifies ATG9A and PTOV1 as new 14-3-3 binding partners, providing mechanistic insight into autophagy and oncogenic signaling in cancer. Using proteomics and targeted biochemical assays, the research details how phosphorylation-dependent interactions regulate protein stability and localization, illuminating new opportunities for targeted cancer interventions.

• Estradiol, GPR30, and ER Stress in CD4+ T Cell Recovery Afte

  2026-05-13

  This study demonstrates that 17β-estradiol restores splenic CD4+ T lymphocyte function after hemorrhagic shock by attenuating endoplasmic reticulum stress through both ERα and GPR30 signaling. The findings clarify how non-classical estrogen pathways contribute to immune normalization, providing targeted mechanistic insights for trauma-induced immunosuppression research.

• Calnexin’s Role in Variant-Specific Rescue of CFTR Mutants

  2026-05-13

  Tedman et al. systematically dissect how calnexin, an ER chaperone, governs expression and pharmacological rescue of over 200 clinical CFTR variants. Their deep mutational scanning approach reveals variant- and domain-dependent modulation of corrector efficacy, offering mechanistic insights critical for advancing targeted cystic fibrosis therapies.

• PP2A-Regulated Autophagy Drives C. albicans Biofilm Resistan

  2026-05-12

  This study uncovers a mechanistic link between protein phosphatase 2A (PP2A) and drug resistance in Candida albicans biofilms through autophagy-related protein phosphorylation. The findings highlight PP2A's central role in modulating antifungal susceptibility, offering a promising target for innovative fungal infection research.

• Nanozyme Hydrogel Disrupts ROS-Ferroptosis-Inflammation Cycl

  2026-05-12

  This study introduces a nanozyme-functionalized hydrogel capable of interrupting the ROS-ferroptosis-inflammation feedback loop in intervertebral disc degeneration (IDD). By leveraging a cerium oxide and black phosphorus nanozyme, the approach achieves durable ROS scavenging and suppresses key inflammatory signaling, offering a promising strategy for disc repair.

• Translating ROS Mechanisms into Precision Assays for Cancer

  2026-05-11

  This thought-leadership article explores how mechanistic insights into reactive oxygen species (ROS) and cuproptosis are reshaping translational oncology. It bridges foundational cell biology with the strategic application of advanced ROS measurement technologies—spotlighting the APExBIO Reactive Oxygen Species Assay Kit and its DCFH-DA fluorescent probe. The discussion contextualizes recent breakthroughs in ROS-responsive cancer therapies and provides actionable protocol parameters, competitive landscape analysis, and a forward-looking outlook for translational researchers.

• Troglitazone as a Precision Tool for SPP1-Targeted Macrophag

  2026-05-11

  Explore how Troglitazone, a leading PPARγ agonist, empowers precise SPP1 modulation in tumor-associated macrophages. This in-depth analysis uniquely bridges molecular assays and emerging immuno-oncology strategies.

• Reactive Oxygen Species Assay Kit: Mechanism, Evidence, and

  2026-05-10

  The Reactive Oxygen Species Assay Kit enables quantitative ROS detection in live cells using the DCFH-DA fluorescent probe. Its validated chemistry, robust controls, and compatibility with various research domains support reliable oxidative stress measurement, especially in cancer and apoptosis research.

• Canagliflozin: SGLT2 Inhibitor Workflows for Renal Research

  2026-05-09

  Canagliflozin, a potent SGLT2 inhibitor, is revolutionizing diabetes and kidney disease research by targeting renal glucose reabsorption and remodeling mitochondrial function. This article delivers actionable protocols, advanced troubleshooting, and data-driven insights for maximizing Canagliflozin’s effectiveness in metabolic and renal studies.

8372 records 13/559 page Previous Next First page 上5页 1112131415 下5页 Last page